Ignyta, Inc. (Nasdaq: RXDX) today announced that an abstract relating to entrectinib, the company’s proprietary oral tyrosine kinase inhibitor targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE